Breaking

U.S. Natural Gas Futures Drop Below $3 for First Time Since 2012
Tweet TWEET

Clinical Study Updates, Collaborations, and Stock Price Updates - Research Report on Medtronic, Regeneron, Celldex, Cubist, and

  Clinical Study Updates, Collaborations, and Stock Price Updates - Research
        Report on Medtronic, Regeneron, Celldex, Cubist, and MannKind

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, December 31, 2013

NEW YORK, December 31, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Medtronic,
Inc. (NYSE: MDT), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Celldex
Therapeutics, Inc. (NASDAQ: CLDX), Cubist Pharmaceuticals Inc. (NASDAQ: CBST),
and MannKind Corp. (NASDAQ: MNKD). Today's readers may access these reports
free of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Medtronic, Inc. Research Report

On December 17, 2013, Medtronic, Inc. (Medtronic) reported that the first
patients were randomized in SYMPLICITY HTN-4, evaluating the Symplicity(TM)
renal denervation system in patients with moderate uncontrolled hypertension
(systolic blood pressure greater than or equal to 140 and less than 160 mm Hg,
despite treatment with three or more anti-hypertensive medications of
different classes). According to the Company, SYMPLICITY HTN-4 will enroll up
to 580 patients with systolic blood pressures greater than or equal to 140 and
less than 160 mm Hg at approximately 100 sites, continuing to target a patient
population in line with the Joint National Committee on the Prevention,
Detection, Evaluation and Treatment of High Blood Pressure (JNC-7), the
American Heart Association and the European Society of Hypertension's
definition of uncontrolled hypertension. Nina Goodheart, Vice President,
General Manager, Renal Denervation, Medtronic, commented, "SYMPLICITY HTN-4
demonstrates Medtronic's commitment to providing randomized safety and
efficacy data for renal denervation in a wide variety of patients, as well as
helping increase our understanding of the potential benefit of renal
denervation for more patients with treatment resistant hypertension." The Full
Research Report on Medtronic, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.AnalystsCorner.com/r/full_research_report/bc94_MDT

--

Regeneron Pharmaceuticals, Inc. Research Report

On December 19, 2013, Regeneron Pharmaceuticals, Inc. (Regeneron) and Sanofi
jointly announced an innovative collaboration with the American College of
Cardiology (ACC) that aims to improve clinical research with alirocumab, an
investigational monoclonal antibody targeting PCSK9 (proprotein convertase
subtilisin/kexin type 9), co-developed by Sanofi and Regeneron. According to
the Company, PCSK9 is known to contribute to circulating low-density
lipoprotein cholesterol (LDL-C) levels. Ralph Brindis, past-President of the
ACC and Senior Medical Officer of External Affairs for the National
Cardiovascular Data Registries (NCDR) said, "This project represents another
example of how medical registries can help transform medicine. The ACC's
registries and related provider networks support quality improvement programs
for practitioners. For the first time, through our PINNACLE ambulatory
office-based registry of the NCDR, we will be helping to solve the difficult
problem of identifying physicians with patients who may be eligible for a
clinical trial." The Full Research Report on Regeneron Pharmaceuticals, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/8ea7_REGN

--

Celldex Therapeutics, Inc. Research Report

On December 26, 2013, Celldex Therapeutics, Inc.'s (Celldex) stock increased
4.30%, ending the day's trading session at $24.03. Over the previous three
trading sessions, shares of Celldex increased 3.04%, compared to the Nasdaq
Composite Index which increased 1.52% during the same period. The Full
Research Report on Celldex Therapeutics, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.AnalystsCorner.com/r/full_research_report/b443_CLDX

--

Cubist Pharmaceuticals Inc. Research Report

On December 26, 2013, Cubist Pharmaceuticals Inc.'s (Cubist) stock declined
0.39%, ending the day's trading session at $66.94. Over the previous three
trading sessions, shares of Cubist declined 0.04%, compared to the Nasdaq
Composite Index which increased 1.52% during the same period. The Full
Research Report on Cubist Pharmaceuticals Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.AnalystsCorner.com/r/full_research_report/92f2_CBST

--

MannKind Corp. Research Report

On December 26, 2013, MannKind Corp.'s (MannKind) stock increased 0.95%,
ending the day's trading session at $5.30. Over the previous three trading
sessions, shares of MannKind increased 5.79%, compared to the Nasdaq Composite
Index which increased 1.52% during the same period. The Full Research Report
on MannKind Corp. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/044e_MNKD

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.